Cell Therapy Human Raw Materials Market Size Report, 2024-2032
Cell Therapy Human Raw Materials Market Size Report, 2024-2032

Cell Therapy Human Raw Materials Market Share, Size, Trends, Industry Analysis Report, By Product (Cell Culture Media, Cell Culture Supplements, Cell Culture Sera, Reagents & Buffers, Others); By End-User; By Region; Segment Forecast, 2024- 2032

  • Published Date:Feb-2024
  • Pages: 117
  • Format: PDF
  • Report ID: PM4546
  • Base Year: 2023
  • Historical Data: 2019-2022

Report Outlook

  • cell therapy human raw materials market size was valued at USD 2.94 billion in 2023.
  • The market is anticipated to grow from USD 3.62 billion in 2024 to USD 19.13 billion by 2032, exhibiting the CAGR of 23.1% during the forecast period.

Market Introduction

The human raw materials in cell therapy is currently experiencing a surge in technological advancements, marked by the development of innovative biomaterials and sophisticated manufacturing processes. These breakthroughs serve to enhance the efficiency and scalability of cell therapy production. Also, there is a noticeable shift towards personalized medicine, placing an increased focus on tailoring cell therapies to individual patient profiles. This evolving trend underscores the imperative for a diverse range of high-quality human raw materials that are essential in supporting the manufacturing of customized cell therapies, eventually contributing to cell therapy human raw materials market growth.

Automation is gaining momentum in the manufacturing processes of cell therapy, aiming to streamline operations and enhance reproducibility. The inclination towards automated workflows in the handling of raw materials reduces the risk of contamination and ensures a consistent approach in cell therapy production.

Cell Therapy Human Raw Materials Market Size

To Understand More About this Research: Request a Free Sample Report

  • For instance, in May 2023, Lonza introduced the TheraPeak T-Vivo cell culture medium, an innovative chemically defined medium designed to enhance the manufacturing of CAR T cells. Devoid of animal-origin components, this medium enhances consistency and process control, streamlining regulatory approval processes for accelerated time-to-market.

The rising incidence of chronic conditions such as cancer, diabetes, and autoimmune disorders, coupled with a growing demand for regenerative and personalized medicines, increasing research and development initiatives, and a surge in investments, are expected to increase the cell therapy human raw materials market size in the forecast period.

Industry Growth Drivers

Increasing occurrence of chronic ailments is projected to spur the product demand.

The cell therapy human raw materials market growth is greatly aided by the mounting prevalence of chronic conditions, including cancer and diabetes, stands as a significant catalyst for the cell therapy market. Cell therapies present inventive treatment avenues that address the underlying causes of these ailments, thereby amplifying the need for human raw materials.

Favorable Regulatory Landscape is expected to drive cell therapy human raw materials market growth.

Governments and regulatory entities are progressively acknowledging the promise of cell therapies and are streamlining the regulatory framework to facilitate their development and commercialization. A regulatory environment that is supportive fosters investments and expedites the expansion of the cell therapy human raw materials market size.

 Cell Therapy Human Raw Material

Industry Challenges

High development cost is likely to impede the market cell therapy human raw materials growth opportunities.

High development cost stand as a prominent factor hindering the growth of the cell therapy human raw materials market. The creation of cell therapies entails substantial research and development expenditures, encompassing costs associated with clinical trials and manufacturing processes. The substantial upfront costs may serve as a hindrance for smaller companies, constraining their engagement in the market.

Moreover, cell therapy manufacturing involves intricate processes demanding precision and adherence to stringent quality benchmarks. The intricacy of production poses challenges in scalability, impacting the cost-effectiveness of cell therapies. Thereby, hindering the cell therapy human raw materials market growth.

 Report Segmentation

The market is primarily segmented based on product, end-user, and region.

By Product

By End-User

By Region

  • Cell Culture Media
  • Cell Culture Supplements
  • Cell Culture Sera
  • Reagents & Buffers
  • Others                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  • Biopharmaceutical & Pharmaceutical Companies
  • CROs & CMOs
  • Academic & Research Institutions
  • North America (U.S., Canada)
  • Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
  • Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
  • Latin America (Brazil, Mexico, Argentina)
  • Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

To Understand the Scope of this Report: Speak to Analyst

By Product Analysis

Cell Culture Media segment is expected to witness highest growth during forecast period

The cell culture media segment is projected to grow at a CAGR during the projected period in the cell therapy human raw materials market. This is propelled by various significant factors. Cell culture media provides a controlled and optimized environment with essential nutrients, growth factors, and other critical components necessary for the survival & proliferation of cells. This controlled environment allows researchers and manufacturers to optimize conditions, ensuring the reproducibility & scalability of cell cultures for therapeutic applications. In addition, numerous companies are making substantial investments in the development of cell culture media to enhance the effectiveness of the cell therapy process.

By End-User Analysis

Biopharmaceutical and pharmaceutical companies segment is expected to dominate the cell therapy human raw materials market during forecast period

In 2023, the cell therapy human raw materials market share was predominantly influenced by biopharmaceutical & pharmaceutical companies, commanding a significant market share. The escalating demand for personalized medicine and regenerative treatments has propelled these companies to focus on developing and commercializing cutting-edge cell therapies. Advancements in technology and a supportive regulatory environment have further incentivized biopharmaceutical and pharmaceutical firms to expand their presence in this burgeoning market. The need for high-quality human raw materials, devoid of animal-origin components, is driving strategic partnerships, acquisitions, and intensified research efforts. This dynamic landscape underscores the pivotal role these companies play in shaping the future of cell therapy and underscores the potential for sustained growth in the industry.

 Cell Therapy Human Raw Material Seg

Regional Insights

North America region dominated the global cell therapy human raw materials market in 2023

North America dominated the global cell therapy human raw materials market in 2023 and is expected to continue to do so. The prevailing influence of the region can be credited to favorable government regulations, a rising need for groundbreaking therapeutics, and concerted endeavors by major market entities to enhance cell-based therapy products addressing various chronic disorders. Additionally, North America hosts numerous prominent companies engaged in the production and commercialization of cell-based products, creating a surge in demand for cell therapy human raw materials and thereby propelling market expansion. Furthermore, collaborative initiatives between key industry players and smaller biotechnology firms heighten competition, as companies strive to fortify their positions in the dynamically evolving cell therapy market.

In the meanwhile, the Asia Pacific region is poised to experience the most rapid growth in the market. This surge is attributed to a heightened emphasis on biotechnology and a growing demand for advanced cell therapies. The market's expansion is further propelled by increased research and development activities, strategic collaborations, and the establishment of manufacturing facilities by major industry players.

 Cell Therapy Human Raw Material Reg

Key Market Players & Competitive Insights

The cell therapy human raw materials market is fragmented and is anticipated to witness competition due to several players' presence. Major service providers in the market are constantly upgrading their technologies to stay ahead of the competition and to ensure efficiency, integrity, and safety. These players focus on partnership, product upgrades, and collaboration to gain a competitive edge over their peers and capture a significant cell therapy human raw materials market share.

Some of the major players operating in the global market include:

  • Bio-Techne Corporation
  • Catalent, Inc.
  • CellGenix GmbH
  • Corning Incorporated
  • Lonza Group Ltd.
  • Merck KGaA
  • Miltenyi Biotec
  • Pall Corporation (Danaher Corporation)
  • PeproTech, Inc.
  • STEMCELL Technologies Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec
  • ZenBio, Inc.
  • RoosterBio Inc.

 Recent Developments

  • In January 2024, Solvias, a leading global provider of Chemistry, Manufacturing, and Control (CMC) analytics, disclosed its commitment to conduct analytical release testing services for the groundbreaking CRISPR/Cas9 genome-edited cell therapy. Under a long-term agreement with Vertex Pharmaceuticals, Solvias will contribute its expertise to CASGEVY, the world's first FDA-approved treatment for sickle cell disease (SCD) in patients aged 12 and above experiencing recurrent vaso-occlusive crises. This collaboration underscores Solvias' role in supporting the advancement and quality control of cutting-edge therapies in the field of genetic medicine.
  • In June 2023, StemCyte revealed the formalization of a collaborative partnership with a prominent U.S. cell therapy enterprise engaged in the creation of allogeneic genetically modified CAR-NK cells derived from umbilical cord blood. Under the agreement, StemCyte commits to providing essential cellular raw materials crucial for the global advancement of allogeneic cell therapy product development.

Report Coverage

The cell therapy human raw materials market report emphasizes on key regions across the globe to provide better understanding of the product to the users. Also, the report provides market insights into recent developments, trends and analyzes the technologies that are gaining traction around the globe. Furthermore, the report covers in-depth qualitative analysis pertaining to various paradigm shifts associated with the transformation of these solutions.

The report provides detailed analysis of the cell therapy human raw materials market size while focusing on various key aspects such as competitive analysis, product, end-user, and their futuristic growth opportunities.

Cell Therapy Human Raw Materials Market Report Scope

Report Attributes


Market size Value in 2024

USD 3.62 billion

Revenue Forecast in 2032

USD 19.13 billion


23.1% from 2024 – 2032

Base Year


Historical Data

2019 – 2022

Forecast Period

2024 – 2032

Quantitative Units

Revenue in USD billion and CAGR from 2024 to 2032

Segments Covered

  • By Product
  • By End-User
  • By Region

Regional Scope

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Competitive Landscape

  • Cell Therapy Human Raw Materials Market Share Analysis (2023)
  • Company Profiles/Industry participants profiling includes company overview, financial information, product/service benchmarking, and recent developments

Report Format

  • PDF + Excel


Report customization as per your requirements with respect to countries, region and segmentation.


The global cell therapy human raw materials market size is expected to reach USD 19.13 billion by 2032

Corning Incorporated, Lonza Group Ltd., Merck KGaA, Miltenyi Biotec, Pall Corporation are the top market players in the market.

North America region contribute notably towards the global Cell Therapy Human Raw Materials Market.

Cell Therapy Human Raw Materials Market is exhibiting the CAGR of 23.1% during the forecast period.

The Cell Therapy Human Raw Materials Market report covering key segments are product, end-user, and region